Julius Li

TL;DR: The utility of cefazolin versus ASPs in the treatment of MSSA bacteremia is highlighted and concerns about susceptibility to hydrolysis by type A β‐lactamases and selective pressures from unnecessary gram‐negative coverage are addressed.

TL;DR: This multicentre evaluation of a stewardship intervention in hospitalized CAP patients reduced the total antibiotic DOT and increased guideline-concordant DOT without adversely affecting patient outcomes.

TL;DR: The existing evidence for first‐ and second‐line treatment regimens that may be considered for special populations such as patients with penicillin allergies, patients with or at risk for QTc‐interval prolongation, and patients who are pregnant, breastfeeding, or elderly are summarized.

TL;DR: The epidemiology of invasive fungal infections in the transplant recipients and susceptibility patterns of the fungi associated with these infections are discussed and the newly approved delayed-release oral tablet and intravenous solution formulations provide additional treatment options by reducing interpatient variability and providing flexibility in these set of critically ill patients.

TL;DR: Current guidelines recommend oral vancomycin or fidaxomicin for the treatment of mild‐to‐moderate Clostridium difficile associated diarrhea (CDAD), while metronidazole is recommended as an alternative when oral van comycin and fidxomicin are unavailable, but data are lacking among the solid organ transplant (SOT) population.